PROSPECT: Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial
The PROSPECT Trial is key to the ongoing search for more effective strategies to prevent serious infection during critical illness in elderly patients around the world.
Deborah Cook, MD, MSc (Epid), FRCPC, DABIM, CCM, CAHS, FRS -- McMaster University
Rationale: Whether probiotics reduce VAP, other infections, or have an impact on antimicrobial stewardship needs to be established.
Hypothesis: By modifying the microbiome and through other mechanisms, probiotics will prevent VAP, decrease other ICU-acquired infections such as Clostridium difficile infection and antibiotic-associated diarrhea, while reducing overall antibiotic use.
Objectives: In frail critically ill patients who need a breathing machine, the PROSPECT Trial will investigate whether oral L. rhamnosus GG (a common probiotic) prevents infections and decreases antibiotic use.
Research Plan: The PROSPECT Trial will enrol patients including those over aged 65 years to test in a randomized trial the effect of twice daily L. rhamnosus GG compared to placebo on VAP and other ICU-acquired infections, diarrhea, antimicrobial use, length of mechanical ventilation, ICU and hospital stay and mortality.
Back to TG 2015-20 Project Page